PEGLIATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH ECTEINASCIDIN 743 (ECTEINESCIDIN 743)

摘要

1. A method of treating a human body for cancer, comprising administering a therapeutically effective amount of a pegylated liposomal form of doxorubicin anthracycline (“PLD”), in combination with a therapeutically effective amount of ET-743.2. The method of claim 1, wherein said therapeutically effective amounts of ET-743 and PLD are administered as part of the same drug or provided as separate drugs for administration at the same time or at different times. The method of claim 1, wherein said therapeutically effective amounts of ET-743 and PLD are provided as separate drugs for administration at different times. The method according to claim 2, wherein said therapeutically effective amounts of ET-743 and PLD are provided as separate drugs for administration at different times. The method of claim 3, wherein said therapeutically effective amount of PLD is administered prior to administration of said effective therapeutic amount of ET-743.6. The method of claim 4, wherein said therapeutically effective amount of PLD is administered prior to administration of said effective therapeutic amount of ET-743.7. The method of claim 2, wherein said therapeutically effective amounts of PLD and ET-743 are administered by intravenous injection. The method of claim 7, wherein the infusion time for intravenous injection is up to 6 hours for said therapeutically effective amount of PLD and up to 24 hours for said therapeutically effective amount of ET-743.9. The method of claim 8, wherein the infusion time for intravenous injection is 1-2 hours for said therapeutically effective amount of PLD and about 3 hours for said therapeutically effective